Scientists map out antiviral Drug's journey in tiny human trial

NCT ID NCT05050682

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study gave a single IV dose of the antiviral PF-07304814 to 5 healthy adults. Researchers measured how much of the drug ended up in urine and feces, and how it was processed in the blood. The goal was simply to understand the drug's breakdown and elimination, not to test if it works against any virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PF-07304814 (an antiviral drug given by IV)

What this could lead to

If successful, this study will help researchers understand how the body handles PF-07304814, which could support future trials for treating viral infections.

What could go wrong

This is a very small, early-phase study in healthy volunteers, not patients. It only looks at how the drug moves through the body, not whether it works against any disease. Results may not predict effectiveness or safety in sick people.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 viral infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fortrea Clinical Research Unit - Madison

    Madison, Wisconsin, 53704, United States